SpringWorks Therapeutics Inc (SWTX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Saqib Islam
Employees:
190
100 WASHINGTON BOULEVARD, STAMFORD, CT 06902
203-883-9490

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.

Data derived from most recent annual or quarterly report
Market Cap 1.956 Billion Shares Outstanding62.382 Million Avg 30-day Volume 654.553 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue0.0 Debt to Equity0.0 EBITDA-226.939 Million
Price to Book Value3.7087 Operating Margin0.0 Enterprise Value867.244 Million
Current Ratio9.796 EPS Growth0 Quick Ratio9.582
1 Yr BETA 1.3649 52-week High/Low 65.92 / 13.6 Profit Margin0.0
Operating Cash Flow Growth-196.6941 Altman Z-Score15.3743 Free Cash Flow to Firm -158.206 Million
Earnings Report2023-02-23

Are you looking for this stock instead?

View SEC Filings from SWTX instead.

View recent insider trading info

Funds Holding SWTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SWTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-12:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-20:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    858 total shares from 1 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    PICHL DANIEL CHIEF PEOPLE OFFICER

    • Officer
    35,203 2023-01-26 3

    PERIER FRANCIS I JR CHIEF FINANCIAL OFFICER

    • Officer
    43,463 2023-01-07 2

    WEINSTEIN HERSCHEL S GENERAL COUNSEL & SECRETARY

    • Officer
    35,830 2023-01-07 2

    ISLAM SAQIB CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    905,104 2023-01-07 2

    NOFI MICHAEL CHIEF ACCOUNTING OFFICER

    • Officer
    16,855 2023-01-07 2

    SMITH L. MARY CHIEF DEVELOPMENT OFFICER

    • Officer
    212,219 2023-01-07 4

    EDRIS BADREDDIN CHIEF OPERATING OFFICER

    • Officer
    720,738 2023-01-05 1

    ASHAR BHAVESH CHIEF COMMERCIAL OFFICER

    • Officer
    161,857 2023-01-05 2

    CASSIDY JAMES CHIEF MEDICAL OFFICER

    • Officer
    230,723 2023-01-05 2

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    • 10% Owner
    5,599,842 2022-09-12 2

    BURGESS MICHAEL F. HEAD OF RESEARCH & DEVELOPMENT

    • Officer
    49,584 2022-07-18 2

    ALBAN CARLOS

    • Director
    40,218 2022-07-14 2

    LYNCH DANIEL

    • Director
    312,519 2022-05-19 1

    SQUINTO STEPHEN P

    • Director
    • 10% Owner
    6,333,277 2022-05-19 1

    FUHRMAN ALAN

    • Director
    21,242 2022-05-19 1

    LEWIS-HALL FREDA C

    • Director
    21,242 2022-05-19 1

    HAMBLETON JULIE

    • Director
    21,242 2022-05-19 1

    SCHWARTZ JEFFREY LAWRENCE

    • Director
    4,852,549 2022-05-19 1

    BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC

    BC SW, LP

    SCHWARTZ JEFFREY LAWRENCE

    KOPPEL ADAM

    • Director
    • 10% Owner
    4,832,413 2021-08-10 0

    RENSTRUP JENS CHIEF MEDICAL OFFICER

    • Officer
    250,499 2021-01-07 0

    PFIZER INC

    PFIZER VENTURES (US) LLC

    • 10% Owner
    4,593,847 2019-09-17 0

    HORN ANDRE R

    • Director
    24,000 2009-05-19 0

    PFEFFER MATTHEW J

    • Director
    0 2009-01-06 0

    SALAS PETER E

    • Director
    20,000 2007-03-01 0

    NEEDHAM & CO LLC

    NEEDHAM GEORGE A

    • 10% Owner
    10,627,446 2006-08-23 0

    NEEDHAM GROUP, INC.

    • 10% Owner
    2,009,807 2006-08-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    PICHL DANIEL - Officer CHIEF PEOPLE OFFICER

    2023-01-27 16:30:40 -0500 2023-01-26 S 858 $31.00 d 35,203 direct yes 5.0167 6.6221 13.8796 4 0.0 1

    WEINSTEIN HERSCHEL S - Officer GENERAL COUNSEL & SECRETARY

    2023-01-10 16:01:27 -0500 2023-01-07 F 909 $26.41 d 35,830 direct 4.233 1.3025 4.9566 3 0.0 1

    SMITH L. MARY - Officer CHIEF DEVELOPMENT OFFICER

    2023-01-10 16:01:53 -0500 2023-01-07 F 1,068 $26.41 d 212,219 direct 4.233 1.3025 4.9566 3 0.0 1

    PERIER FRANCIS I JR - Officer CHIEF FINANCIAL OFFICER

    2023-01-10 16:02:13 -0500 2023-01-07 F 1,090 $26.41 d 43,463 direct 4.233 1.3025 4.9566 3 0.0 1

    PICHL DANIEL - Officer CHIEF PEOPLE OFFICER

    2023-01-10 16:02:40 -0500 2023-01-07 F 546 $26.41 d 36,061 direct 4.233 1.3025 4.9566 3 0.0 1

    EDRIS BADREDDIN - Officer CHIEF OPERATING OFFICER

    2023-01-10 16:05:03 -0500 2023-01-07 F 1,483 $26.41 d 237,223 direct 4.233 1.3025 4.9566 3 0.0 1

    ISLAM SAQIB - Director - Officer CHIEF EXECUTIVE OFFICER

    2023-01-10 16:07:24 -0500 2023-01-07 F 4,097 $26.41 d 905,104 direct 4.233 1.3025 4.9566 3 0.0 1

    NOFI MICHAEL - Officer CHIEF ACCOUNTING OFFICER

    2023-01-10 16:08:00 -0500 2023-01-07 F 409 $26.41 d 16,855 direct 4.233 1.3025 4.9566 3 0.0 1

    WEINSTEIN HERSCHEL S - Officer GENERAL COUNSEL & SECRETARY

    2023-01-09 16:59:46 -0500 2023-01-06 F 1,782 $27.52 d 36,739 direct 2.2568 5.1794 7.3252 4 0.0 1

    ASHAR BHAVESH - Officer CHIEF COMMERCIAL OFFICER

    2023-01-09 17:00:14 -0500 2023-01-06 F 1,665 $27.52 d 45,096 direct 2.2568 5.1794 7.3252 4 0.0 1

    NOFI MICHAEL - Officer CHIEF ACCOUNTING OFFICER

    2023-01-09 17:00:40 -0500 2023-01-06 F 783 $27.52 d 17,264 direct 2.2568 5.1794 7.3252 4 0.0 1

    EDRIS BADREDDIN - Officer CHIEF OPERATING OFFICER

    2023-01-09 17:01:19 -0500 2023-01-06 F 3,326 $27.52 d 238,706 direct 2.2568 5.1794 7.3252 4 0.0 1

    SMITH L. MARY - Officer CHIEF DEVELOPMENT OFFICER

    2023-01-09 17:00:43 -0500 2023-01-06 F 2,452 $27.52 d 213,287 direct 2.2568 5.1794 7.3252 4 0.0 1

    PERIER FRANCIS I JR - Officer CHIEF FINANCIAL OFFICER

    2023-01-09 17:01:52 -0500 2023-01-06 F 2,374 $27.52 d 44,553 direct 2.2568 5.1794 7.3252 4 0.0 1

    PICHL DANIEL - Officer CHIEF PEOPLE OFFICER

    2023-01-09 16:59:23 -0500 2023-01-06 F 1,719 $27.52 d 36,607 direct 2.2568 5.1794 7.3252 4 0.0 1

    ISLAM SAQIB - Director - Officer CHIEF EXECUTIVE OFFICER

    2023-01-09 17:01:35 -0500 2023-01-06 F 8,400 $27.52 d 909,201 direct 2.2568 5.1794 7.3252 4 0.0 1

    CASSIDY JAMES - Officer CHIEF MEDICAL OFFICER

    2023-01-09 17:00:56 -0500 2023-01-06 F 1,263 $27.52 d 47,230 direct 2.2568 5.1794 7.3252 4 0.0 1

    EDRIS BADREDDIN - Officer CHIEF OPERATING OFFICER

    2023-01-09 17:01:19 -0500 2023-01-05 A 105,000 a 105,000 direct

    CASSIDY JAMES - Officer CHIEF MEDICAL OFFICER

    2023-01-09 17:00:56 -0500 2023-01-05 A 65,000 a 65,000 direct

    EDRIS BADREDDIN - Officer CHIEF OPERATING OFFICER

    2023-01-09 17:01:19 -0500 2023-01-05 A 135,000 a 135,000 direct

    ISLAM SAQIB - Director - Officer CHIEF EXECUTIVE OFFICER

    2023-01-09 17:01:35 -0500 2023-01-05 A 84,175 a 917,601 direct 2.2568 5.1794 7.3252 4 0.0 1

    ISLAM SAQIB - Director - Officer CHIEF EXECUTIVE OFFICER

    2023-01-09 17:01:35 -0500 2023-01-05 A 260,000 a 260,000 direct

    PERIER FRANCIS I JR - Officer CHIEF FINANCIAL OFFICER

    2023-01-09 17:01:52 -0500 2023-01-05 A 19,425 a 46,927 direct 2.2568 5.1794 7.3252 4 0.0 1

    PERIER FRANCIS I JR - Officer CHIEF FINANCIAL OFFICER

    2023-01-09 17:01:52 -0500 2023-01-05 A 60,000 a 60,000 direct

    PERIER FRANCIS I JR - Officer CHIEF FINANCIAL OFFICER

    2023-01-09 17:01:52 -0500 2023-01-05 A 65,000 a 65,000 direct

    NOFI MICHAEL - Officer CHIEF ACCOUNTING OFFICER

    2023-01-09 17:00:40 -0500 2023-01-05 A 9,713 a 18,047 direct 2.2568 5.1794 7.3252 4 0.0 1

    PICHL DANIEL - Officer CHIEF PEOPLE OFFICER

    2023-01-09 16:59:23 -0500 2023-01-05 A 19,425 a 38,326 direct 2.2568 5.1794 7.3252 4 0.0 1

    PICHL DANIEL - Officer CHIEF PEOPLE OFFICER

    2023-01-09 16:59:23 -0500 2023-01-05 A 60,000 a 60,000 direct

    PICHL DANIEL - Officer CHIEF PEOPLE OFFICER

    2023-01-09 16:59:23 -0500 2023-01-05 A 65,000 a 65,000 direct

    WEINSTEIN HERSCHEL S - Officer GENERAL COUNSEL & SECRETARY

    2023-01-09 16:59:46 -0500 2023-01-05 A 19,425 a 38,521 direct 2.2568 5.1794 7.3252 4 0.0 1

    WEINSTEIN HERSCHEL S - Officer GENERAL COUNSEL & SECRETARY

    2023-01-09 16:59:46 -0500 2023-01-05 A 60,000 a 60,000 direct

    WEINSTEIN HERSCHEL S - Officer GENERAL COUNSEL & SECRETARY

    2023-01-09 16:59:46 -0500 2023-01-05 A 65,000 a 65,000 direct

    ASHAR BHAVESH - Officer CHIEF COMMERCIAL OFFICER

    2023-01-09 17:00:14 -0500 2023-01-05 A 22,663 a 46,761 direct 2.2568 5.1794 7.3252 4 0.0 1

    ASHAR BHAVESH - Officer CHIEF COMMERCIAL OFFICER

    2023-01-09 17:00:14 -0500 2023-01-05 A 70,000 a 70,000 direct

    EDRIS BADREDDIN - Officer CHIEF OPERATING OFFICER

    2023-01-09 17:01:19 -0500 2023-01-05 A 33,994 a 242,032 direct 2.2568 5.1794 7.3252 4 0.0 1

    NOFI MICHAEL - Officer CHIEF ACCOUNTING OFFICER

    2023-01-09 17:00:40 -0500 2023-01-05 A 30,000 a 30,000 direct

    NOFI MICHAEL - Officer CHIEF ACCOUNTING OFFICER

    2023-01-09 17:00:40 -0500 2023-01-05 A 35,000 a 35,000 direct

    SMITH L. MARY - Officer CHIEF DEVELOPMENT OFFICER

    2023-01-09 17:00:43 -0500 2023-01-05 A 22,663 a 215,739 direct 2.2568 5.1794 7.3252 4 0.0 1

    SMITH L. MARY - Officer CHIEF DEVELOPMENT OFFICER

    2023-01-09 17:00:43 -0500 2023-01-05 A 65,000 a 65,000 direct

    SMITH L. MARY - Officer CHIEF DEVELOPMENT OFFICER

    2023-01-09 17:00:43 -0500 2023-01-05 A 70,000 a 70,000 direct

    CASSIDY JAMES - Officer CHIEF MEDICAL OFFICER

    2023-01-09 17:00:56 -0500 2023-01-05 A 22,663 a 48,493 direct 2.2568 5.1794 7.3252 4 0.0 1

    CASSIDY JAMES - Officer CHIEF MEDICAL OFFICER

    2023-01-09 17:00:56 -0500 2023-01-05 A 70,000 a 70,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 19:15:04 UTC 4.2661 0.3039 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 18:45:03 UTC 4.2661 0.3039 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 18:15:03 UTC 4.2661 0.3039 350000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 17:45:03 UTC 4.2661 0.3039 350000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 17:15:03 UTC 4.2661 0.3039 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 16:45:03 UTC 4.2608 0.3092 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 16:15:03 UTC 4.2608 0.3092 350000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 15:45:03 UTC 4.2608 0.3092 350000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 15:15:04 UTC 4.2608 0.3092 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 14:45:04 UTC 4.2608 0.3092 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 14:15:04 UTC 4.2608 0.3092 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 13:45:04 UTC 4.2396 0.3304 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 13:15:03 UTC 4.2396 0.3304 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-08 12:45:04 UTC 4.2396 0.3304 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-07 22:15:03 UTC 4.2396 0.3304 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-07 21:45:03 UTC 4.2396 0.3304 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-07 21:15:03 UTC 4.2396 0.3304 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-07 20:45:04 UTC 4.2344 0.3356 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-07 20:15:03 UTC 4.2344 0.3356 750000
    SPRINGWORKS THERAPEUTICS INC SWTX 2023-02-07 19:45:04 UTC 4.2344 0.3356 750000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund SWTX -7.0 shares, $-189.0 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund SWTX -6.0 shares, $-162.0 2020-03-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity Fund SWTX -370.0 shares, $-26584.5 2021-11-30 N-PORT
    VANGUARD MONTGOMERY FUNDS- VANGUARD MARKET NEUTRAL FUND SWTX -24000.0 shares, $-684720.0 2022-09-30 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity ETF SWTX -1424.0 shares, $-34432.32 2022-11-30 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Christopher L. Jacobs republican House Filing 2023-01-10 2022-12-12 P $1,001-$15,000

    Elevate your investments